| dc.contributor.author |
Mahesh, R. |
|
| dc.date.accessioned |
2023-11-21T06:41:36Z |
|
| dc.date.available |
2023-11-21T06:41:36Z |
|
| dc.date.issued |
2015 |
|
| dc.identifier.uri |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399007/ |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13204 |
|
| dc.description.abstract |
In the last few decades, serotonin type-3 (5-HT3) receptor antagonists have been identified as potential targets for anxiety disorders. In preclinical studies, 5-HT3 antagonists have shown promising antianxiety effects. In this study, a novel 5-HT3 receptor antagonist, QCM-13(N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) was evaluated for anxiolytic-like activity in rodent behavioral test battery. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
PMC |
en_US |
| dc.subject |
Pharmacy |
en_US |
| dc.subject |
PMC |
en_US |
| dc.subject |
Anti-anxiety agent |
en_US |
| dc.title |
Pharmacological evaluation of novel 5-HT3 receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery |
en_US |
| dc.type |
Article |
en_US |